Slide 1: Q4 & Full Year FY24 Earnings Call
Q4 & Full Year FY24 Earnings Call May 16th, 2024
Slide 2: Safe Harbor Statement
Safe Harbor Statement Certain statements in this release concerning our future growth prospects are forward-looking statements, which are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those contemplated in such forward-looking s
Slide 3: Group CEO Opening Remarks
Group CEO Opening Remarks $ Biocon
Slide 4: Opening Remarks: Q4 & full year FY24
Opening Remarks: Q4 & full year FY24 • FY24 has been a year of balanced progress • Biocon Generics, Biocon Biologics and Syngene have delivered significant operational successes, also faced and addressed a range of operational challenges Generics: • Strong growth in our formulations business driven
Slide 5: Financial Highlights Q4 and full year FY24
Financial Highlights Q4 and full year FY24
Slide 6: Opening Remarks: Financial Highlights – Q4 FY24
Opening Remarks: Financial Highlights – Q4 FY24 In INR Cr Q4 FY24 Q4 FY23 Q3 FY24 YoY (%) QoQ(%) Generics 719 744 703 (3) 2 Biosimilars 2,358 2,102 2,4831 12 (5) Novels - 19 - - - Research Services 917 994 854 (8) 7 Revenue from Operations 3,917 3,774 3,9541 4 (1) Total Revenue 3,966 3,929 4,5192 1
Slide 7: Opening Remarks: Financial Highlights – FY24
Opening Remarks: Financial Highlights – FY24 In INR Cr FY24 FY23 YoY (%) Generics 2,799 2,765 1 Biosimilars 8,8241 5,584 58 Novels - 19 - Research Services 3,489 3,193 9 Revenue from Operations 14,7561 11,174 32 Total Revenue 15,6212 11,550 35 R&D 1,154 1,119 3 % of Revenue (Ex. Syngene) 10% 14% Cor
Slide 8: Generics Q4 and full year FY24
Generics Q4 and full year FY24
Slide 9: Biocon Generics: Q4 & full year FY24 Business Performance update
Biocon Generics: Q4 & full year FY24 Business Performance update Strong traction in the formulations business (up 36% YoY), led by growth of Q4 Q4 Q3 In ₹ Cr YoY % QoQ % statins and immunosuppressants across all major geographies during FY24 FY24 FY23 FY24 Revenue from 719 744 703 (3) 2 Operations D
Slide 10: Biosimilars Q4 and full year FY24
Biosimilars Q4 and full year FY24
Slide 11: Biocon Biologics: Biosimilars – Q4 FY24 Business Update
Biocon Biologics: Biosimilars – Q4 FY24 Business Update Key Products’ Market Share1 United States 1st quarter where Biocon Biologics directly managed the acquired business across geographies Mar-24 Jan-24 Mar-23 Fulphila (bPegfilgrastim) 21% 19% 14% Ogivri (bTrastuzumab) 18% 14% 10% Continued increa
Slide 12: Biocon Biologics: Biosimilars – Q4 & full year FY24 Financial Update
Biocon Biologics: Biosimilars – Q4 & full year FY24 Financial Update Q4 Q4 Q3 YoY QoQ In INR CR FY24 FY23 FY24 % % Revenue from 2,358 2,102 2,4832 12 103 Operations Q4 revenue grew 12% vs. LY and 10% on a sequential quarter basis after adjusting for income from the non-core BFI divesture in Q3 FY24
Slide 13: Biocon Biologics: Biosimilars – Q4 FY24 Other Business Updates
Biocon Biologics: Biosimilars – Q4 FY24 Other Business Updates FDA accepted bUstekinumab filing and settled with J&J for a launch in the US no later than Feb’25 – will be among the first wave of entrants Settled with Bayer and Regeneron for a launch of bAflibercept in Canada no later than July’25 Dw
Slide 14: Novels Q4 and full year FY24
Novels Q4 and full year FY24
Slide 15: Novel Molecules: FY24 update
Novel Molecules: FY24 update During the fiscal, Equillium presented positive data from Phase 1b EQUALISE Study of itolizumab in patients with lupus nephritis at the annual meetings of America Society of Nephrology and the American College of Rheumatology In April 2024, Equillium announced positive t
Slide 16: Research Services Q4 and full year FY24
Research Services Q4 and full year FY24
Slide 17: Syngene: Q4 and full year FY24 Update
Syngene: Q4 and full year FY24 Update Q4 Q4 Q3 YoY QoQ Q4 and FY24 impacted by lower demand for research services stemming from a In INR Cr FY24 FY23 FY24 % % slowdown in US biotech funding environment Revenue from 917 994 854 (8) 7 Operations Full year performance supported by strong growth in deve
Slide 18: Concluding Remarks
Concluding Remarks
Slide 19: Concluding Remarks: Q4 & full year FY24
Concluding Remarks: Q4 & full year FY24 • FY24 has been a year of significant operational success and clear progress across business segments • FY25 to be a year of both consolidation and of transitional and accelerating growth • Revenue growth to pick up in H2 of the fiscal year • Generics • Growth
Slide 20: Q&A
Q&A